Investigator Award

(Chicago, Illinois) — June 15, 2024
ExoMira Medicine is proud to announce that co-founder Dr. Huiping Liu, MD, PhD, has been named a Chan Zuckerberg Biohub Chicago Investigator. This prestigious appointment recognizes Dr. Liu’s pioneering work in cancer biology and translational oncology, particularly in the areas of tumor cell plasticity, metastasis, and treatment resistance—fields that directly inform ExoMira’s scientific mission.

The Investigator award includes multiyear research funding from the Chan Zuckerberg Initiative (CZI), supporting Dr. Liu’s work from June 2024 through May 2027. As part of the Biohub Chicago community, Dr. Liu will collaborate with other leading scientists across institutions to advance high-impact, collaborative biomedical research aimed at understanding and curing disease.

ExoMira congratulates Dr. Liu on this significant honor, which reflects the broader scientific excellence driving the company’s development of novel cancer immunotherapies.